New stroke drug safety showdown: 4,500 patients to test bleeding risks
NCT ID NCT07519889
First seen May 01, 2026 · Last updated May 23, 2026 · Updated 5 times
Summary
This study will compare the safety of two clot-dissolving medicines, rhTNK-tPA and rt-PA, in about 4,500 adults who have had a stroke. Participants will receive one of the drugs within 4.5 hours of symptoms starting. The main goal is to see if the newer drug, rhTNK-tPA, causes fewer brain bleeds than the standard treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE ISCHEMIC STROKE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.